Table 2

Adherence by treatment and HbA1c response from baseline to 1 year, showing overall decrement in HbA1c by group

DrugNPercentage of patients with MPR <80% Change in HbA1c from baseline to 12 months for patients with MPR <80% (95% CI)Change in HbA1c from baseline to 12 months for patients with MPR ≥80% (95% CI)Difference between change in HbA1c from baseline to 12 months for patients with <80% MPR ≥80% (95% CI)P
CPRD
 All treatments38,10013.3−0.75 (−0.78, −0.72) [−8.2 (−8.5, −7.9)]−1.14 (−1.16, −1.13) [−12.5 (−12.7, −12.4)]−0.40 (−0.43, −0.37) [−4.4 (−4.7, −4.0)]<0.001
 Metformin13,82318.8−0.78 (−0.82, −0.74) [−8.5 (−9.0, −8.1)]−1.16 (−1.18, −1.14) [−12.7 (−12.9, −12.5)]−0.38 (−0.42, −0.34) [−4.2 (−4.6, −3.7)]<0.001
 Sulfonylurea10,07011.9−0.85 (−0.91, −0.79) [−9.3 (−10.0, −8.6)]−1.23 (−1.24, −1.20) [−13.4 (−13.6, −13.1)−0.38 (−0.44, −0.31) [−4.1 (−4.8, −3.4)]<0.001
 Thiazolidinedione9,0888.6−0.66 (−0.73, −0.59) [−7.2 (−8.0, −6.4)]−1.24 (−1.25, −1.21) [−13.4 (−13.7, −13.2)]−0.57 (−0.64, −0.49) [−6.2 (−7.0, −5.4)]<0.001
 DPP4i5,1199.1−0.40 (−0.50, −0.30) [−4.4 (−5.5, −3.3)]−0.83 (−0.87, −0.81) [−9.1 (−9.5, −8.8)]−0.44 (−0.54, −0.33) [−4.8 (−5.9, −3.6)]<0.001
GoDARTS
 All2,62215.1−0.63 (−0.74, −0.52) [−6.9 (−8.1, −5.7)]−1.09 (−1.14, −1.04) [−11.9 (−12.5, −11.4)]−0.46 (−0.58, −0.34) [−5.0 (−6.3, −3.7)]<0.001
 Metformin97218.1−0.59 (−0.73, −0.43) [−6.4 (−8.0, −4.7)]−1.08 (−1.14, −1.01) [−11.8 (−12.5, −11.0)]−0.49 (−0.66, −0.32) [−5.4 (−7.2, −3.5)]<0.001
 Sulfonylurea72916.2−0.77 (−0.99, −0.56) [−8.4 (−10.8, −6.1)]−1.11 (−1.20, −1.02) [−12.1 (−13.1, −11.1)]−0.34 (−0.58, −0.1) [−3.7 (−6.3, −1.1)]<0.005
 Thiazolidinedione67711.4−0.70 (−0.95, −0.44) [−7.6 (−10.4, −4.8)]−1.28 (−1.37, −1.18) [−14.0 (−15.0, −12.9)]−0.59 (−0.86, −0.32) [−6.4 (−9.4, −3.5)]<0.001
 DPP4i24410.70.12 (−0.32, 0.56) [1.3 (−3.5, 6.1)]−0.63 (−0.79, −0.48) [−6.9 (−8.6, −5.3)]−0.75 (−1.22, −0.28) [−8.2 (−13.3, −3.1)]<0.005
  • HbA1c is reported in % [mmol/mol]. HbA1c change adjusted by baseline HbA1c.